The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HIV-1. Unfortunately, most antibodies to HIV-1 are narrow in their specificity, and a basic understanding of how to develop antibodies with broad neutralizing activity is needed. Designing methods to target antibodies to conserved HIV-1 epitopes may allow for the generation of broadly neutralizing antibodies and aid the global fight against AIDS by providing new approaches to block HIV-1 infection. Using a naturally occurring HIV-1 Envelope (Env) variant as a template, we sought to identify features of Env that would enhance exposure of conserved HIV-1 epitopes.Within a cohort study of high-risk women in Mombasa, Kenya, we previously identified...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The human immunodeficiency virus type 1 (HIV-1) variants that are transmitted to newly infected indi...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
HIV envelope protein (Env) is the sole target of broadly neutralizing antibodies (BNAbs) that are ca...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
Recent studies have shown that natural infection by HIV-2 leads to the elicitation of high titers of...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...
The generation of broadly neutralizing antibodies is a priority in the design of vaccines against HI...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
The human immunodeficiency virus type 1 (HIV-1) variants that are transmitted to newly infected indi...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
HIV-1 affects over 34 million people worldwide. Although there is no vaccine, some patients develop ...
Broadly neutralizing antibodies (bNAbs), which develop over time in some HIV-1-infected individuals,...
HIV envelope protein (Env) is the sole target of broadly neutralizing antibodies (BNAbs) that are ca...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
Recent studies have shown that natural infection by HIV-2 leads to the elicitation of high titers of...
A comprehensive understanding of the regions on HIV-1 envelope trimers targeted by broadly neutraliz...
Over 30 years after the emergence of HIV-1, there is no effective vaccine, and AIDS remains an impor...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...
International audienceBackground: Highly potent broadly neutralizing monoclonal antibodies (bNAbs) h...